PHAT Q3 2024 Earnings — Phathom Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

PHATPhathom Pharmaceuticals, Inc.

$891M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M

Gross Profit

$14M85.6% margin

Operating Income

-$71M-433.0% margin

Net Income

-$86M-523.3% margin

EPS (Diluted)

$-1.32

QoQ Revenue Growth

+123.3%

Cash Flow

Operating Cash Flow

-$64M

Free Cash Flow

-$63M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$387M

Total Liabilities

$574M

Stockholders' Equity

-$187M

Cash & Equivalents

$335M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$0	—
Gross Profit	$14M	-$121,000	+11666.9%
Operating Income	-$71M	-$36M	-98.5%
Net Income	-$86M	-$43M	-97.9%